title: Cabergoline for suppression of puerperal lactation in a prevention of mother-to-child HIV-transmission programme in rural Malawi.
abstract: This study shows that cabergoline (single oral-dose) is an acceptable, safe and effective drug for suppressing puerperal lactation. It could be of operational benefit not only for artificial feeding, but also for weaning in those that breast-feed within preventive mother-to-child HIV transmission programmes in resource-limited settings.
authors.affiliation: Medecins sans Frontieres, Thyolo District, Malawi.
authors.forename: L
authors.initials: L
authors.lastname: Buhendwa
authors.forename: R
authors.initials: R
authors.lastname: Zachariah
authors.forename: R
authors.initials: R
authors.lastname: Teck
authors.forename: M
authors.initials: M
authors.lastname: Massaquoi
authors.forename: J
authors.initials: J
authors.lastname: Kazima
authors.forename: P
authors.initials: P
authors.lastname: Firmenich
authors.forename: A D
authors.initials: AD
authors.lastname: Harries
mesh_terms: D000328:Adult; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D015658:HIV Infections / Q000635:transmission*; D006801:Humans; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D007774:Lactation / Q000187:drug effects*; D008295:Malawi; D049590:Postpartum Period; D011388:Prolactin / Q000037:antagonists & inhibitors; D012424:Rural Population
chemical_list: D018491:Dopamine Agonists; D004873:Ergolines; D011388:Prolactin; D000077465:Cabergoline